Paul Zolkind

High-avidity TCR signaling drives an NKG2A-positive CD8 T cell exhaustion state in human tumors

This study identifies high-avidity TCR signaling via NFAT as a key driver of NKG2A-positive CD8 T cell exhaustion in human tumors, with implications for immunotherapy.

Suppression of NRF2-dependent cancer growth by a covalent allosteric molecular glue

This paper introduces VVD-065, a covalent NRF2 inhibitor that enhances NRF2 degradation and sensitizes tumors to therapy, supporting a Phase I clinical trial.

Pyrimethamine and a potent analogue WCDD115 inhibit NRF2 by suppressing DHFR and one-carbon metabolism

This paper identifies Pyrimethamine and its derivative WCDD115 as potent inhibitors of NRF2 by targeting DHFR and one-carbon metabolism, with WCDD115 showing 22-fold greater efficacy.